Takeda Adds Theravance GI Candidate In Deal Flurry
This article was originally published in PharmAsia News
In its third licensing deal this week, Takeda is allying with Theravance for the global development of a gastrointestinal agent that will bolster its core portfolio in this area.
You may also be interested in...
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.